BioNixus does. We are a healthcare and pharmaceutical market research company founded in 2012, with regional leadership in Cairo, London and Sheridan, Wyoming (US headquarters) and field offices in Dubai and Al Khobar. BioNixus is fully operational in LATAM, delivered from its USA offices with BioNixus field teams in Brazil and LATAM, and is in the process of opening a São Paulo office by the end of 2026. For obesity, we map each stage where patients fall out of care or switch: when they first raise weight with a doctor, how obesity gets diagnosed and coded, the choice between lifestyle care, GLP-1-based medicines and bariatric surgery, how treatment is paid for, starting and dose-stepping, and whether patients persist, switch or stop. Fieldwork is in Gulf Arabic and English, drawing on a network of about 3,200 physicians. Custom studies are priced from $10k to $60k.
GCC · Obesity · GLP-1
Patient Journey Research GCC: Obesity, GLP-1 and Chronic Disease
Last reviewed: 5 October 2026
8–12 weeks
Multi-country timeline
$10k–$60k
Cost range
5+
Stakeholder types
48 hours
scoped proposal
Quick answer
Who runs patient journey research for obesity in the GCC?
Decision framework
GCC patient journey research: decision framework
Why journey research is a launch prerequisite in GCC
GCC markets have high chronic disease burden but low treatment rates in many conditions. Journey research reveals whether the addressable patient population is constrained by diagnosis gaps, referral friction, or treatment initiation barriers — each requiring a different commercial response.
What journey research must capture in GCC
The dual government-private pathway, family and caregiver roles in decision-making, Arabic-language qualitative depth, stigma dynamics in sensitive disease areas, and country-level variations between KSA, UAE, and smaller GCC markets.
What to do with journey outputs
Rank friction points by magnitude and type, map commercial and medical intervention hypotheses to each friction, and use the journey framework to align brand strategy, medical education, and patient support programme design.
What patient journey research is and why it matters in GCC
Patient journey research is the systematic mapping and analysis of the sequence of experiences, decisions, and touchpoints a patient with a specific medical condition moves through — from the first awareness that something is wrong, through help-seeking and diagnosis, specialist referral, treatment selection, initiation, and ongoing adherence or persistence. In its richest form, it integrates the patient's subjective experience and emotional state at each stage with the structural and system-level factors that shape their pathway.
For pharmaceutical teams launching in GCC markets, patient journey research matters because it reveals the actual size and structure of the addressable patient population — which is often smaller and more fragmented than epidemiological prevalence data would suggest. A condition with 18% adult prevalence in KSA or 19% in UAE is not generating equivalent commercial opportunity if 40–50% of those patients remain undiagnosed, another 20–25% are diagnosed but not treated, and a further 15% are treated but not persistent beyond 90 days. Journey research maps exactly where patients are lost and why.
Beyond market sizing, journey research provides the evidence base for medical education strategy (which diagnosis gaps need HCP-level intervention?), patient support programme design (what adherence barriers need addressing at treatment initiation?), and formulary and access argumentation (what patient burden narrative supports reimbursement priority?). It is both a pre-launch planning tool and a lifecycle evidence asset.
GCC-specific journey features
Several structural characteristics of GCC healthcare systems create journey dynamics that differ from European or North American norms and must be captured explicitly in research design.
Late diagnosis culture. In chronic conditions with gradual symptom onset — type 2 diabetes, hypertension, certain cancers, and many autoimmune diseases — GCC patients often present for formal diagnosis only when symptoms become disabling or acute. Cultural factors contribute: stoicism, reluctance to seek medical attention for non-acute symptoms, and a tendency to manage early symptoms through dietary or religious practices before engaging the healthcare system. In KSA, research consistently shows that a significant proportion of newly diagnosed type 2 diabetes patients have had detectable glycaemic abnormality for 3–7 years before diagnosis. This creates a diagnosis gap that is commercially significant — treatments targeting early intervention cannot reach patients who are not in the system.
High specialist referral barriers. The GCC healthcare system is built around hospital-based specialists rather than primary care gatekeepers in the way European systems are structured. In KSA, the MOH primary care system exists but has historically been under-resourced and lacks the continuity of care model that enables reliable chronic disease management. Patients with chronic conditions often seek specialist care directly but face queuing and access barriers within the government hospital system — referral wait times of 4–12 weeks for government specialist appointments are common for non-urgent conditions. This creates a gap in the journey between initial symptom recognition and specialist engagement that is longer and more variable than in European markets.
Dual government and private care pathways. Many GCC patients — particularly in KSA and UAE — navigate both government and private care simultaneously, exploiting the complementary strengths of each. The government sector offers subsidised or free medicines but has longer wait times and less personalised interaction. The private sector offers faster access and more time with physicians but carries out-of-pocket or insurance costs. A patient's journey may involve initial diagnosis in a private clinic, specialist follow-up in a government hospital (to access subsidised medicines), and pharmacy management back in a private pharmacy. These hybrid pathways create complexity for commercial teams — which sector touchpoints matter most for prescribing behaviour, product recommendations, and patient education?
Family and caregiver involvement. Health decision-making in GCC is frequently collective rather than individual. In conditions affecting older patients, or in contexts where cultural norms around patient autonomy are more limited — particularly for female patients in traditional households — family members play a direct and active role in decisions about whether to seek care, which physician to visit, whether to fill a prescription, and whether to continue a treatment regimen. Journey research that interviews only the patient without capturing the caregiver perspective will systematically under-record a major source of pathway friction and decision influence. BioNixus designs GCC journey studies to include caregiver interviews as a standard stakeholder segment.
Disease areas
Key disease areas for GCC patient journey research
Certain disease areas have particularly rich journey research value in GCC due to the combination of high prevalence, complex pathway dynamics, and significant commercial opportunity.
Obesity and GLP-1 patient journeys
Obesity journeys in the GCC are long, self-managed for years, and increasingly split between GLP-1 medicines, bariatric surgery and self-pay clinics. Published evidence shows why the journey, not just prevalence, decides the commercial opportunity:
- The first conversation comes late. In the ACTION-IO survey in Saudi Arabia (1,000 people with obesity and 200 healthcare professionals, fielded in 2018), people with obesity spent a mean of 6 years (median 4 years) struggling with their weight before they first discussed it with a healthcare professional. Only 5% kept off a weight loss of 5% or more for over a year. (ACTION-IO Saudi Arabia, PMC8265404; study sponsored by Novo Nordisk)
- Doctors and patients read motivation differently. In the same survey, 50% of people with obesity said they were motivated to lose weight. Only 39% of healthcare professionals thought their patients were. (PMC8265404)
- Discontinuation and switching are common. In a 2024 survey of adults in Kuwait using GLP-1 receptor agonists for weight loss, 47% had stopped treatment. The main reasons were side effects, reaching their goal, and cost. The study also reports that GLP-1 RAs are free in government facilities, but shortages and long waits push patients to private clinics. (Frontiers in Nutrition, PMC12127183)
- Coverage rules shape the path. Abu Dhabi's Department of Health publishes a Thiqa reimbursement policy for obesity medications with eligibility criteria (DoH policy PDF). Elsewhere, many patients pay out of pocket, so the same molecule can follow very different journeys by emirate and payer.
What a BioNixus obesity journey study maps:
- Self-management years: diets, supplements, clinics and social-media advice before any doctor is involved.
- First HCP conversation: who raises weight (patient or doctor), in which setting (primary care, endocrinology, private clinic), and what stops it.
- Diagnosis and coding: whether obesity is recorded as a disease, plus the comorbidities (type 2 diabetes, hypertension, sleep apnoea) that trigger action.
- Treatment choice: lifestyle programmes, GLP-1-based medicines (semaglutide, tirzepatide), and bariatric and metabolic surgery referral.
- Access and payment: government supply, insurer criteria and prior authorisation, or self-pay. Includes supply shortages and pharmacy substitution.
- Initiation and dose-stepping: first fill, injection training, early side effects, and follow-up cadence.
- Persistence, switching and stopping: why patients switch molecule or channel, stop for cost or tolerability, or stop on reaching their goal.
- Maintenance and weight regain: what happens after stopping, and how the journey hands over to (or from) bariatric surgery.
Country pages: Saudi Arabia obesity & GLP-1 research · UAE obesity market · Kuwait obesity market · Egypt obesity & GLP-1 research · GCC obesity market hub
Diabetes and metabolic disease. Type 2 diabetes adult prevalence is estimated at approximately 18–19% in both KSA and UAE — among the highest rates globally — with pre-diabetes prevalence adding another 10–15%. The treatment landscape encompasses oral antidiabetic agents, GLP-1 receptor agonists, SGLT-2 inhibitors, insulin, and combination therapies. The journey for a newly diagnosed patient is complex: initial GP management, specialist referral decision (diabetologist vs. endocrinologist vs. GP-continued management), education provision, device choice for insulin users, and long-term adherence to often complex regimens. Journey research here maps the critical branch points that determine whether patients receive optimal therapy.
Oncology. Cancer diagnosis and management pathways in GCC have unique characteristics. Late-stage presentation is a persistent challenge — many GCC cancer patients are diagnosed at stage III or IV, partly due to lower screening programme uptake compared with Europe or North America, and partly due to the late-diagnosis culture described above. The journey from symptom recognition to oncology consultation can involve multiple GP and general medicine encounters before referral, particularly in KSA's tiered government hospital system. For pharma teams launching oncology products in GCC, understanding these diagnosis gaps and the referral-to-treatment timeline is critical for realistic launch uptake projections.
Cardiovascular disease. Cardiovascular disease is the leading cause of death across most GCC countries, with hypertension and dyslipidaemia as the predominant risk drivers. The patient journey for cardiovascular risk management often begins in primary care or occupational health settings (particularly in KSA's large corporate employer health programmes) but transitions to cardiology for established disease. Adherence to long-term cardiovascular medications is a well-documented challenge in GCC — rates of statin discontinuation after 12 months have been reported as high as 50–60% in some GCC cohort studies, substantially higher than European benchmarks. Journey research in this area quantifies and maps the specific adherence barrier structure.
Respiratory disease. Asthma and COPD represent significant but historically undertreated disease areas in GCC. High rates of smoking in male GCC populations, alongside occupational dust and chemical exposures, drive a substantial COPD burden. Asthma management pathways often involve over-reliance on short-acting rescue inhalers and under-prescription of maintenance therapy. The journey from symptom recognition to appropriate inhaler therapy involves multiple prescribing decisions where journey research can identify intervention opportunities.
Fieldwork
Stakeholder mapping in GCC patient journey research
A comprehensive GCC patient journey study maps the perspectives and roles of multiple stakeholder groups across the pathway. Each stakeholder type provides a different lens on the journey and different data type.
Patients provide the experiential journey narrative — what they felt, believed, and decided at each stage, and what barriers or facilitators they encountered. Qualitative depth interviews with patients (8–15 per country for qualitative saturation) are the primary method, supplemented by online diaries for real-time journey capture. Recruiting patients through HCP referral (snowball from treating physician) or patient support organisations provides higher quality participants than open recruitment.
Caregivers provide the family decision-making perspective. For conditions affecting older patients, patients with limited health literacy, or conditions with significant functional impact (severe asthma, advanced cancer, insulin-dependent diabetes), caregiver interviews often reveal as much pathway-relevant data as patient interviews. BioNixus designs GCC journey studies with a dedicated caregiver interview quota of 4–8 per country alongside the patient interview programme.
General practitioners and primary care physicians are the journey gatekeepers for most non-emergency conditions. GP IDIs (5–8 per country) map the referral decision criteria, the diagnostic barriers at primary care level, and the GP's understanding of what specialist care offers that they cannot provide.
Specialist physicians provide the detailed treatment decision framework — what information they have when they first see a patient, how they select therapy, and what support or monitoring they provide. Specialist IDIs (6–10 per country) are the core clinical data source for the treatment initiation and management stages of the journey.
Pharmacists provide a window into treatment initiation friction, adherence support capability, and the interaction between prescribed therapy and actual dispensing. Community pharmacist interviews (4–6 per country) are particularly valuable for oral therapies and self-administered injectables.
Payers provide the system-level perspective on access barriers, coverage policies, and formulary restrictions that shape which treatments patients can access and at what cost. Payer interviews (3–5 per country for GCC journey research) complete the stakeholder picture and are essential when the journey includes a reimbursement or cost barrier stage.
For obesity journeys we add the people who control the GLP-1 and surgery decision points: endocrinologists and obesity physicians, family physicians, bariatric and metabolic surgeons, dietitians, community and hospital pharmacists, and payer, TPA and insurance medical directors. We also interview people living with obesity (current, past and never-treated GLP-1 users) and, where relevant, family members involved in the decision.
Touchpoints
Touchpoint analysis: mapping the end-to-end GCC journey
GCC patient journey research structures the touchpoint sequence across eight key stages, each of which can be analysed for friction severity, stakeholder involvement, and intervention opportunity.
Stage 1 — Symptom awareness. When and how does the patient first notice that something is abnormal? What does the symptom mean to them? Do they associate it with a medical condition or attribute it to fatigue, diet, or ageing? GCC research consistently shows that symptom interpretation is shaped by cultural health beliefs, family normative comparisons ("everyone in my family has this"), and low awareness of early-stage disease presentations.
Stage 2 — Help-seeking decision. The decision to seek medical care is not automatic — it is influenced by perceived severity, social pressure (family encouragement or discouragement), access costs, and stigma. In GCC, this decision is often delayed relative to Western norms for non-acute conditions. The help-seeking stage is where the largest diagnosis delays typically originate.
Stage 3 — First medical contact. Who does the patient see first? GP, emergency department, occupational health, or a private specialist? In UAE, self-referral to specialists is common given insurance coverage and easy access. In KSA, the MOH gatekeeper model means first contact is more likely to be a primary care physician within the government system. The choice of first contact determines the subsequent referral pathway.
Stage 4 — Diagnosis. The diagnostic stage maps the time and touchpoints between first medical contact and confirmed diagnosis. Referral-to-diagnosis gap analysis is a key output — how many weeks or months between first symptom presentation and confirmed diagnosis? What investigations were performed and in what sequence? Were there missed opportunities for earlier diagnosis?
Stage 5 — Specialist referral. For conditions requiring specialist management, the referral process is a critical journey stage. Referral wait times, the quality of information transferred in the referral letter, and patient expectations of what specialist care will involve all affect the diagnosis-to-treatment-initiation timeline. Delays at this stage are a significant source of commercial opportunity loss.
Stage 6 — Treatment selection and initiation. This is the primary commercial stage — the therapy selection decision, formulary constraints that shape which treatments are available at which cost, patient education at initiation, and the first-fill experience. Research here maps prescribing criteria, the role of treatment guidelines vs. formulary vs. personal experience, and what information the patient receives at initiation.
Stage 7 — Adherence and monitoring. The 90-day and 12-month adherence stage captures whether patients continue treatment as prescribed, what drives early discontinuation, what the monitoring cadence looks like, and what support (if any) the patient receives. In GCC, this is where many therapy brands lose a disproportionate share of their patient base relative to European benchmarks.
Stage 8 — Persistence and long-term management. The long-term management stage captures disease progression, regimen intensification decisions, and the patient's accumulated experience of the healthcare system. It is also where secondary complications and co-morbidity management increasingly dominate the healthcare interaction.
Method
Arabic-language qualitative research for patient journey work
Qualitative patient research in GCC requires Arabic as the primary interview language in most markets. Patients in KSA, Kuwait, Qatar, and Bahrain predominantly prefer Arabic for healthcare discussions, and Gulf-dialect Arabic — which differs in vocabulary and register from Egyptian or Levantine Arabic — is the appropriate conversational register for KSA and Gulf patient interviews. BioNixus deploys Gulf Arabic-speaking qualitative researchers who are trained in health psychology interviewing techniques and who can discuss sensitive topics (disease impact, stigma, financial hardship, family dynamics) with the cultural competence required for authentic responses.
Topic guide development for Arabic patient research requires specific considerations. Direct questions about sensitive disease experiences (e.g., impact on sexual function in diabetes, family burden in oncology, social limitations in severe respiratory disease) require indirect framing in Arabic to avoid social desirability bias and premature interview termination. Narrative interviewing techniques — asking patients to "tell the story" of their illness rather than answering direct structured questions — tend to produce richer and more authentic data in GCC cultural contexts than highly structured closed probing.
Patient consent in Gulf Arabic is mandatory for all GCC patient research, and the consent process itself must be conducted in the patient's preferred language by the interviewer, not simply presented as a document. For patients with low health literacy or who are unfamiliar with research participation, the consent explanation should be supplemented by a simple verbal summary of what participation involves and what will happen to their information.
Cost
Cost and timelines
Patient journey studies are priced as custom research, from $10k to $60k, depending on the number of markets, stakeholder types and methods (for example, adding a patient diary or payer interviews). Typical timelines from confirmed brief:
| Design | Typical timeline |
|---|---|
| Single-market qualitative journey (KSA or UAE): patient, HCP and caregiver interviews | 6–8 weeks to raw data |
| Three-market GCC journey (e.g. KSA, UAE, Kuwait) | 8–12 weeks |
| Journey study with online patient diary (4–6 week diary run) plus interviews | 14–18 weeks |
| Journey study with payer interviews and chart review added | 12–16 weeks |
We send a scoped proposal within 48 hours of a brief.
GCC patient journey research benchmarks
Multi-country timeline
8–12 weeks
From confirmed brief to raw data delivery for a three-market GCC qualitative journey study.
Cost range
$10k–$60k
Custom research, from $10k to $60k.
Stakeholder types
5+
Patients, caregivers, GPs, specialists, pharmacists, and payers mapped across the journey.
Questions
Patient journey research GCC: frequently asked questions
Patient journey research obesity GCC: who can run it for a pharma team?
BioNixus runs patient journey research for obesity across the GCC and Egypt, led from our Dubai office (Thuraya Tower 1, 5th Floor, Al Sufouh 2, Dubai) with a KSA office in Al Khobar and a MENA regional office in Cairo. Studies combine patient, caregiver, prescriber, pharmacist and payer interviews in Gulf Arabic and English.
How do you map the obesity patient journey in the GCC?
We map eight stages: self-management, first HCP conversation, diagnosis and coding, treatment choice (lifestyle, GLP-1-based medicines, bariatric surgery), access and payment, initiation, persistence or switching or stopping, and maintenance. Each stage is scored for where patients are lost and why, with country cuts for KSA, the UAE, Kuwait and other GCC markets.
Can you study GLP-1 discontinuation and switching in Saudi Arabia, the UAE and Kuwait?
Yes. We interview current and past users of GLP-1-based medicines and their prescribers and pharmacists to find out why patients stop (cost, side effects, supply, reaching their goal) or switch molecule or channel. Published Kuwait data show this matters: 47% of GLP-1 users surveyed in 2024 had stopped treatment.
Who do you interview in an obesity patient journey study?
People living with obesity and, where relevant, family members. Endocrinologists and obesity physicians, family physicians, bariatric and metabolic surgeons, dietitians, community and hospital pharmacists, and payer, TPA or insurer medical directors. We recruit through a network of about 3,200 physicians.
Does the obesity journey differ by payer in the GCC?
Yes. Government supply, insurer criteria and self-pay produce different journeys for the same medicine. Abu Dhabi's Department of Health, for example, publishes a Thiqa reimbursement policy for obesity medications, while many patients elsewhere pay out of pocket. We map who pays at each stage and how that changes initiation and persistence.
How long does a GCC patient journey study take, and what does it cost?
A three-market GCC journey study typically takes 8–12 weeks from confirmed brief to raw data, and 14–18 weeks with an online patient diary. Patient journey studies are custom research priced from $10k to $60k, depending on markets, stakeholders and methods.
Which other disease areas do you cover with patient journey research?
Besides obesity, we run GCC patient journey studies in diabetes and metabolic disease, oncology, cardiovascular disease and respiratory disease (asthma and COPD), and link them to adherence, patient support programme and real-world evidence work.